Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk-Reference-Cited by-同舟云学术

Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk

Published:2005-09 Issue:3 Volume:46 Page:492-499
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Franklin Stanley S.¹,Wachtell Kristian¹,Papademetriou Vasilios¹,Olsen Michael H.¹,Devereux Richard B.¹,Fyhrquist Frej¹,Ibsen Hans¹,Kjeldsen Sverre E.¹,Dahlöf Björn¹

Affiliation:

1. From the Heart Disease Prevention Program, University of California, Irvine (S.S.F.); Copenhagen County University Hospital, Glostrup, Denmark (K.W., M.H.O., H.I.); VA Medical Center, Washington DC (V.P.); Weill Medical College of Cornell University, New York, NY (K.W., R.B.D.); Helsinki University Central Hospital, Finland (F.F.); Ullevål University Hospital, Oslo, Norway (S.E.K.); Sahlgrenska University Hospital-Östra, Gothenburg, Sweden (B.D.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference19 articles.

1. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

3. Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy

4. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation

5. Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antihypertensive Potential of Pistacia lentiscus var. Chia: Molecular Insights and Therapeutic Implications;Nutrients;2024-07-05

2. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension;Cochrane Database of Systematic Reviews;2018-11-14

3. A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines;Current Cardiology Reports;2016-02-03

4. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension;Cochrane Database of Systematic Reviews;2015-01-11

5. Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders;Expert Review of Cardiovascular Therapy;2014-12